Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + BCG in High-Risk NMIBC (TACBIN-01)
NCT04922047Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Renji Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04922047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922047.